Low-Voltage Area Ablation in Addition to Pulmonary Vein Isolation in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Stefano ValcherAlessandro VillaschiGiulio FalasconiMauro ChiaritoFilippo GiuntiLaura NovelliLucio AddeoAntonio TaorminaCristina PanicoPietro FranciaAndrea SagliettoGuido Del MonacoAlessia Chiara LatiniSebastiano CarliStefano FrittellaAlessandro Giaj LevraGiulia AntonelliAlberto PredaFabrizio GuarraciniPatrizio MazzoneAntonio BerruezoMassimo TrittoGianluigi CondorelliDiego PenelaPublished in: Journal of clinical medicine (2024)
Background: Low-voltage area (LVA) ablation, in addition to pulmonary vein isolation (PVI), has been proposed as a new strategy in patients with atrial fibrillation (AF), but clinical trials have shown conflicting results. We performed a systematic review and meta-analysis to assess the impact of LVA ablation in patient undergoing AF ablation (PROSPERO-registered CRD42024537696). Methods: Randomized clinical trials investigating the role of LVA ablation in addition to PVI in patients with AF were searched on PubMed, Embase, and the Cochrane Library from inception to 22 April 2024. Primary outcome was atrial arrhythmia recurrence after the first AF ablation procedure. Secondary endpoints included procedure time, fluoroscopy time, and procedure-related complication rate. Sensitivity analysis including only patients with LVA demonstration at mapping and multiple subgroups analyses were also performed. Results: 1547 patients from 7 studies were included. LVA ablation in addition to PVI reduced atrial arrhythmia recurrence (odds ratio [OR] 0.65, 95% confidence interval [CI] 0.52-0.81, p < 0.001) with a number needed to treat to prevent recurrence of 10. No difference in procedure time (mean difference [MD] -5.32 min, 95% CI -19.01-8.46 min, p = 0.45), fluoroscopy time (MD -1.10 min, 95% CI -2.48-0.28 min, p = 0.12) and complication rate (OR 0.81, 95% CI 0.40-1.61, p = 0.54) was observed. Consistent results were demonstrated when considering only patients with LVA during mapping and in prespecified subgroups for AF type (paroxysmal vs. persistent), multicentric vs. monocentric trial, and ablation strategy in control group. Conclusions : In patients with AF, ablation of LVAs in addition to PVI reduces atrial arrhythmia recurrence without a significant increase in procedure time, fluoroscopy time, or complication rate.
Keyphrases
- catheter ablation
- atrial fibrillation
- left atrial
- clinical trial
- radiofrequency ablation
- heart failure
- minimally invasive
- high resolution
- ejection fraction
- end stage renal disease
- newly diagnosed
- prognostic factors
- molecular dynamics
- open label
- case report
- mass spectrometry
- study protocol
- phase iii
- chronic kidney disease
- patient reported